Pfizer takes an option on a drug from Bind; Alnylam CEO Maraganore takes on Shkreli controversy;

@FierceBiotech: GlaxoSmithKline's asthma injection heads for EU approval. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: BIO boots Martin Shkreli's Turing out after pricing controversy erupts. Article | Follow @JohnCFierce

@DamianFierce: Hard to believe but the pope just described biotech valuations as "stretched." | Follow @DamianFierce

> Pfizer ($PFE) has taken an option to develop a new drug candidate from Cambridge, MA-based Bind Therapeutics ($BIND), triggering a $2.5 million payment. Release

> The viral controversy over Martin Shkreli's move to grab quick profits from an old drug has leaders of the biotech industry working overtime to publicly separate the biotech industry from Turing's actions. Alnylam ($ALNY) CEO John Maraganore took to CNBC to say that Shkreli's move has nothing to do with an industry focused on developing new therapies rather than raising prices on old ones. Story

Medical Device News

@FierceMedDev: ICYMI: LabCorp, China's Fosun Pharma, lead Asia-heavy $15B investment in Ativa Medical. FierceDiagnostics Item | Follow @FierceMedDev

@VarunSaxena2: Four key medical device recalls of 2015. Feature | Follow @VarunSaxena2

@EmilyWFierce: Human Longevity joins with South African insurer for $250 exome sequencing service. FierceDiagnostics story | Follow @EmilyWFierce

> Stealth surgical robotics startup from Intuitive Surgical co-founder raises $150M. More

> EU regulators crack down on Brazilian devicemaker for implant safety scare. Story

> St. Jude launches new patient-monitoring interface for CardioMEMS heart failure monitor. Article

Pharma News

@FiercePharma: Mylan leverages marketing savvy, price hikes to make EpiPen a go-to med. More | Follow @FiercePharma

@EricPFierce: We all know about drug recalls but who tops the list for device recalls? FierceMedicalDevices feature | Follow @EricPFierce

> Novartis brings heart, cancer meds to low-income countries for $1 per month. More

> U.S. cancer drug prices up to 3X higher than in Europe: Study. Article

Vaccines News

> IDRI, Wellcome Trust to take tuberculosis jab to PhIIa in South Africa. Story

> Inovio-led team picks up $24M from DARPA to develop Ebola vaccine, treatments. Report

> Serum Institute sets out for dengue fast track. Article

> Scripps Florida nets 4-year, $6M grant from Gates Foundation for HIV vaccine. Story

> Advaxis reports 'encouraging' PhII cervical cancer vaccine data. More

CRO News

> U.K. CRO Venn buys up another contractor. Item

> ShangPharma plots a $60M splash for biologics R&D in China. Story

> German CRO cozies up to Bayer at its Berlin R&D hub. More

> Covance plots a deeper dive into manufacturing. Story

> BioClinica reaches into regulatory affairs with its latest buy. Article

Pharma Manufacturing News

> World's largest reinsurer ready to insure against FDA actions. Report

> Sun Pharma recalls more than 216,000 bottles after label leaches chemical. News

> Aesica plant to get power from biomass plant. More

> Mayne kicks off work on new $65M North Carolina plant. Story

> Pfizer finds buyer for Indian plant set to close this month. Article

Pharma Asia News

> Serum Institute of India throttles back on equity sale. Item

> China-focused RuiYi starts PhI in China on autoimmune candidate RYI-008. News

> HK-listed Lee's Pharmaceutical branches out further with Armetheon deal. More

> Japan's MHLW lines up about 50 candidates for fast-track 'sakigake' process. Story

> Australian subsidies for newer drugs go begging as companies avoid paper chase. Article

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.